Lineage Cell Therapeutics, Inc. announced that the results of imaging analyses demonstrating rapid improvement in outer retinal structure from patients enrolled in a Phase 1/2a clinical study of RG6501 (OpRegen), which were reviewed by multiple, independent reviewers, were presented at the 23rd EURETINA Congress. RG6501 (OpRegan) is a suspension of human allogeneic retinal pigmented epithelial (RPE) cells currently in development for the treatment of GA secondary to age-related macular degeneration (AMD). OpRegen subretinal delivery has the potential to counteract RPE cell loss in areas of GA lesions by supporting retinal cell health and improving retinal structure and function.

It is being developed under an exclusive worldwide collaboration between Lineage, Roche, and Genentech, a member of the Roche Group, and is currently being evaluated in a Phase 2a clinical study in patients with GA secondary to AMD. These data suggest that OpRegen RPE cells may provide direct support to the patients' remaining retinal cells within atrophic areas, and that the improvements to retinal structure can be detected within the first three months following a single administration. 23rd EURETINA Congress Highlights: All 5 patients enrolled in cohort 4 who had extensive coverage of the GA lesion with the surgical bleb containing OpRegen in suspension, demonstrated evidence of improvement in outer retinal structure as assessed by optical coherence tomography (OCT) within the first 3 months after treatment.

A Phase 2a study evaluating the success of OpRegen delivery to target areas of GA is currently enrolling patients.